12:00 AM
Jul 23, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Brivanib: Phase III data

The double-blind, international Phase III BRISK-FL trial in 1,155 patients with advanced HCC who have not received prior systemic therapy showed that first-line treatment with once-daily 800 mg oral brivanib missed the primary endpoint of non-inferiority to sorafenib in improving OS. Details were not disclosed. Bristol-Myers said it is considering options for the product's development...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >